Form 4: Cogent Biosciences CEO Awarded 915,000 Stock Options

Cogent Biosciences' CEO, Andrew R. Robbins, was granted 915,000 stock options on January 23, 2025, which vest over four years.

Summary

• Andrew R. Robbins, the President and CEO of Cogent Biosciences, was granted 915,000 stock options on January 23, 2025.
• These options have an exercise price of $8.89 per share.
• The options will vest in equal monthly installments over a four-year period.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There is no indication of any negative sentiment.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of four years is also typical, encouraging long-term performance and retention.
• The exercise price of $8.89 is a common method of setting the price at the time of the grant.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cogent Biosciences, COGT, Andrew R. Robbins